A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
Huichung Tina Ling
No relevant relationships to disclose
Franco Muggia
No relevant relationships to disclose
James L. Speyer
No relevant relationships to disclose
John Patrick Curtin
No relevant relationships to disclose
Stephanie V. Blank
No relevant relationships to disclose
Leslie R. Boyd
No relevant relationships to disclose
Bhavana Pothuri
No relevant relationships to disclose
Xiaochun Li
No relevant relationships to disclose
Judith D. Goldberg
No relevant relationships to disclose
Amy Tiersten
Research Funding - Genentech